Inflammatory Bowel Disease (IBD)
Asacol
Asacol® 800 mg tablets (mesalazine) is first-line treatment for mild to moderate ulcerative colitis (UC).
Asacol is indicated for the treatment of the inflamed lining of the large bowel (colonic and rectal mucosa) and is the first-line treatment for mild to moderate ulcerative colitis.
The World’s Leading Mesalazine
Asacol contains mesalazine and is available as tablets in 400 and 800mg strengths.
Available in clinics and all major retail pharmacies.
Key Features & Benefits
-
Maintains clinical remission in 9 out of 10 UC patients at 6 months -
Maximum dose where it is needed -
Highest mucosal absorption -
Remission rate of 90%